John A. Stalfort III - Nov 22, 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: VRCA
Transactions as of: Nov 22, 2024
Transactions value $: $0
Form type: 4
Date filed: 11/26/2024, 04:15 PM
Previous filing: Jun 10, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRCA	Common Stock	Purchase		+1.12M	+160.47%		1.82M	Nov 22, 2024	Direct	F1
transaction	VRCA	Common Stock	Gift	$0	+50K	+2.74%	$0.00	1.87M	Nov 26, 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRCA	Series A Warrants (right to buy)	Purchase		+562K			562K	Nov 22, 2024	Common Stock	562K	$1.07	Direct	F1
transaction	VRCA	Series B Warrants (right to buy)	Purchase		+562K			562K	Nov 22, 2024	Common Stock	562K	$1.34	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

Content

The reported securities are included within 1,123,595 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.